Overcoming The Manufacturing and Regulatory Challenges for Gene Therapies: From Bench to Patients

Download key takeaways from this illuminating event, in your free event summary from Pharma Ignite, presented in partnership with Thermo Fisher Scientific.

Capture critical insights into:

The most significant factors to consider when developing CGTs for rare diseases
Regulatory requirements for the FDA and the EMA and how they differ
What to focus on to attain success with FDA and EMA
The key for streamlining development and minimizing costs for future cell and gene therapy development

Sign up to our content service and access now

Your company email address

Please select your industry: (max 1)
Which technology is of interest? (max 1)
Would you like to request a demo? (max 1)

Opt In?

By you requesting this resource, you agree to our terms of use. All data is protected by our Privacy Notice. You can change your contact preferences here. If you have any further questions please get in contact.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
Thermo Fisher Scientific (including its affiliates) may contact me about events, products, services and promotions which Thermo Fisher believes may be of interest to me via email and will process my Personal Information according to its privacy policy. I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com. I acknowledge Thermo Fisher Scientific (including its affiliates) will process my Personal Information according to its Privacy Policy, which includes information about my rights

Overcoming The Manufacturing and Regulatory Challenges for Gene Therapies: From Bench to Patients

Sign up to our content service and access now

Opt In?

Explore similar content

Resiliency and innovation - Navigating the current biotech landscape

Immune checkpoint inhibitors: A breakthrough for immunotherapy

HIV – Global Clinical Trial Landscape